scholarly journals SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)

The Prostate ◽  
2021 ◽  
Author(s):  
Giuseppe Broggi ◽  
Arturo Lo Giudice ◽  
Marina Di Mauro ◽  
Maria Giovanna Asmundo ◽  
Elisabetta Pricoco ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Tissue Microarray ◽  
Microvessel Density ◽  
Immunohistochemical Analysis ◽  
Patients With Diabetes

scholarly journals Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting

1998 ◽  
Vol 78 (7) ◽  
pp. 940-944 ◽  
Author(s):  
M Borre ◽  
BV Offersen ◽  
B Nerstrøm ◽  
J Overgaard
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Microvessel Density ◽  
Watchful Waiting

scholarly journals Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy

The Prostate ◽  
2014 ◽  
Vol 75 (1) ◽  
pp. 84-91 ◽  
Author(s):  
Yasuyoshi Miyata ◽  
Kensuke Mitsunari ◽  
Akihiro Asai ◽  
Kosuke Takehara ◽  
Yasushi Mochizuki ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
Microvessel Density ◽  
Prognostic Role

Prognostic value of microvessel density in prostate cancer: a tissue microarray study

2009 ◽  
Vol 28 (6) ◽  
pp. 687-692 ◽  
Author(s):  
Andreas Erbersdobler ◽  
Hendrik Isbarn ◽  
Kira Dix ◽  
Isabel Steiner ◽  
Thorsten Schlomm ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tissue Microarray ◽  
Microvessel Density ◽  
Prognostic Value ◽  
Microarray Study

scholarly journals A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients

2017 ◽  
Vol 4 (1) ◽  
Author(s):  
Qing Zhong ◽  
Tiannan Guo ◽  
Markus Rechsteiner ◽  
Jan H. Rüschoff ◽  
Niels Rupp ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Tissue Microarray ◽  
Outcome Data ◽  
Clinical Outcome Data

Immunohistochemical Analysis of Prostein Expression in Archived Prostatic Core Biopsies from Prostate Cancer Patients in Western Kenya

2021 ◽  
Author(s):  
Omondi Swaya Tyrus ◽  
Dedan Opondo ◽  
David O. Atandi ◽  
Benard Guyah ◽  
Ng’wena Gideon Magak
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Core Biopsy ◽  
Staining Pattern ◽  
Immunohistochemical Analysis ◽  
Composite Score ◽  
Prostate Tissue ◽  
Diagnostic Utility ◽  
Western Kenya ◽  
Low Sensitivity

Abstract Background Prostate cancer is the leading cause of cancer-associated mortality in men. Most of the current biomarkers for detection of the disease have low sensitivity and specificity. Prostein is a newly reported prostate cancer biomarkers whose diagnostic utility can help in early detection of the disease. Nonetheless, previous studies have utilized limited number of samples to evaluate its immunohistochemistry (IHC) and reports on the African population are not available. The current study aimed to determine the prostein expression in archived prostatic core biopsies from prostate cancer patients in Western Kenya. Materials and Methods This was a retrospective study conducted on malignant and benign prostatic tissue core biopsies of 106 patients who underwent prostate core biopsy at Jaramogi Oginga Odinga Teaching and Referral Hospital and division of urology at Synergy Clinics, Kisumu between January 2018 to May 2021. Immunohistochemical technique was performed on each of the 106 samples and on the following non-prostatic male control biopsies; Testis, Penis, Liver and Esophagus. Cellular location of prostein staining was evaluated at X40, X100 and X400 magnification using a light microscope and was classified as cytoplasmic or nucleocytoplasmic. Intensity of prostein expression was assessed for each core biopsy at similar magnification and graded according the immunohistochemistry composite score. Results The biopsies had been obtained from men whose mean (SE) age was 72.00±0.93 years. 95.3% (101) of the biopsies were malignant and 4.7% (5) were benign. Four non-prostatic male tissues were included. 97% of malignant and all the benign prostate tissue stained positive for prostein whereas the four non-prostatic male tissues were negative. Staining intensities were weak (24.5%), Moderate (17.0%), strong (55.7%) and non-stained (2.8%). The staining was highly immunolocalized within the cytoplasm (95.1% cases) as compared to nucleocytoplasmic (2.0% cases). The mean immunoreactivity composite score was 1.91±0.96 (0.0-3.14). Strongly stained sections had a punctate plasma membrane staining pattern clustered within the cytoplasm in a perinuclear location whereas the weakly stained sections had faint and punctate coarse brown cytoplasmic granular appearing. Conclusion Prostein is exclusively expressed in benign and malignant prostate tissue with a higher cytoplasmic granular staining pattern in the present population. These findings suggest that prostein diagnostic utility is applicable in the current study population and routine IHC diagnosis of prostate cancer may be recommended.

660: Altered MUC-1 (EMA) Protein Expression Studied by Tissue Microarray Predicts Biochemical Failure after Radical Prostatectomy in Prostate Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 222-222
Author(s):  
Mireia Musquera ◽  
Maria J. Ribal ◽  
Yolanda Arce ◽  
Humberto Villavicencio ◽  
Fernando Algaba ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Protein Expression ◽  
Tissue Microarray ◽  
Biochemical Failure

390: Durable Cancer Control in High Risk Prostate Cancer Patients Treated with Radical Prostatectomy

2007 ◽  
Vol 177 (4S) ◽  
pp. 130-130
Author(s):  
Markus Graefen ◽  
Jochen Walz ◽  
Andrea Gallina ◽  
Felix K.-H. Chun ◽  
Alwyn M. Reuther ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Cancer Control ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document